Boardroom Alpha
Start trial
10-K primary document
PODD · Annual Report (Form 10-K) · Filed February 18, 2026

Insulet Corp — 10-K exhibit

podd-exx1055_20251231x10k.htm
Insulet Corp on Boardroom Alpha
Document
Exhibit 10.55

CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. OMISSIONS ARE MARKED [***]

First Amendment to Commercialization Agreement
Regarding Agreed Markets
This First Amendment (this “Amendment”) is entered into as of January 5, 2026 (the “Amendment Effective Date”) by and between Insulet Corporation, a Delaware corporation having a principal place of business at 100 Nagog Park, Acton, MA 01720 (“Insulet”), and DexCom, Inc., having a principal place of business at 6340 Sequence Drive, San Diego, CA 92121 (“DexCom”, and together with Tandem, the “Parties,” and each, a “Party”), with respect to that certain Commercialization Agreement dated as of November 21, 2019 (as amended from time to time, the “Agreement”).
The Parties agree as follows:
As of the Amendment Effective Date, Exhibit 1.2 (Agreed Markets) to the Agreement is hereby amended as follows:
(a)“[***]” and “[***]” are hereby added to the existing list of Agreed Markets; and
(b)“[***]” is hereby deleted and replaced with “[***]”.
An updated Exhibit 1.2 reflecting these changes is attached hereto.
Except as expressly provided in this Amendment, all of the terms and provisions of the Agreement are and will remain in full force and effect. From and after the Amendment Effective Date, each reference in the Agreement to “this Agreement,” “the Agreement,” “hereunder,” “hereof,” “herein,” or words of like import will mean and be a reference to the Agreement as amended by this Amendment. This Amendment is governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflict of laws provisions of such State. This Amendment may be executed in counterparts, each of which is deemed an original, but all of which constitute one and the same agreement. Delivery of an executed counterpart of this Amendment electronically shall be effective as delivery of an original executed counterpart of this Amendment.


The Parties have executed this Amendment as of the Amendment Effective Date.
DEXCOM, INC.
INSULET CORPORATION
By: /s/ Christophe Cantenot
By: /s/ Adam Cate
Print Name: Christophe Cantenot
Print Name: Adam Cate
Title: VP, Finance and Corporate Controller
Title: GVP, Omnipod 5 Franchise Head



Exhibit 1.2
Agreed Markets
[***]

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer